David W. Meline - Aug 9, 2022 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role: Chief Financial Officer
Signature: /s/ Brian Sandstrom, as Attorney-in-Fact
Stock symbol: MRNA
Transactions as of: Aug 9, 2022
Transactions value $: -$28,481
Form type: 4
Date filed: 8/11/2022, 04:52 PM
Previous filing: May 12, 2022
Next filing: Oct 16, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MRNA	Common Stock	Options Exercise	$0	+348	+13.02%	$0.00	3.02K	Aug 9, 2022	Direct	F1, F2
transaction	MRNA	Common Stock	Sale	-$28.5K	-164	-5.43%	$173.66	2.86K	Aug 10, 2022	Direct	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MRNA	Restricted Stock Units	Options Exercise	$0	-348	-9.09%	$0.00	3.48K	Aug 9, 2022	Common Stock	348	$0.00	Direct	F1, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Restricted stock units convert into common stock on a one-for-one basis.
F2	Includes 90 shares acquired under the Moderna, Inc. 2018 Employee Stock Purchase Plan on May 31, 2022.
F3	Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
F4	25% of the shares subject to this restricted stock unit award vested on February 9, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter.